Alprax0.25 mg

Alprax is a short-acting benzodiazepine indicated for the following conditions:

Established / FDA-approved uses

• Generalized Anxiety Disorder (GAD): Short-term relief of symptoms of anxiety, or anxiety associated with depressive symptoms.
• Panic disorder: With or without agoraphobia, in adults.

Not indicated for

Alprax is not indicated for the routine treatment of stress or anxiety of everyday life, and is generally not recommended as a first-line or long-term treatment given its potential for dependence.

Each tablet of Alprazolam contains Alprazolam USP as the active ingredient. It is commonly available as immediate-release tablets (typical strengths 0.25 mg, 0.5 mg, 1 mg) and, in some markets, extended-release tablets and orally disintegrating tablets. Excipient content varies by manufacturer and formulation.

Alprax is a triazolo-benzodiazepine, a class of drugs that act on the central nervous system. It is one of the most commonly prescribed short-acting benzodiazepines for anxiety and panic disorders. Alprax has a relatively rapid onset of action and a short to intermediate elimination half-life compared with other benzodiazepines, which contributes to both its therapeutic usefulness and its recognized potential for misuse, tolerance, and physical dependence.

Benzodiazepine (Anxiolytic / Sedative-Hypnotic agent); Schedule IV controlled substance in most jurisdictions.

Alprazolam exerts its pharmacologic effects by binding to specific sites on the GABA-A receptor complex in the central nervous system, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. This increases chloride ion influx through the GABA-gated chloride channel, producing neuronal hyperpolarization and reduced neuronal excitability. This mechanism underlies the anxiolytic, sedative, muscle-relaxant, and anticonvulsant properties of Alprazolam.

Pharmacokinetics: Alprazolam is well absorbed after oral administration, with peak plasma concentrations reached in 1-2 hours (immediate-release). It is extensively metabolized in the liver primarily by the CYP3A4 enzyme system to active and inactive metabolites, and is excreted mainly in urine. The elimination half-life is approximately 11-16 hours in healthy adults, which may be prolonged in the elderly, in obesity, and in hepatic impairment.

Alprax is taken orally, with or without food, generally in divided doses two to three times daily due to its short duration of action. Tablets should be swallowed whole (or as directed for orally disintegrating formulations, placed on the tongue without water). Doses should be taken at consistent times each day. Do not increase the dose or frequency of Alprax on your own, and do not stop taking it suddenly without consulting a physician, as this can precipitate withdrawal.

Clinically significant interactions

• Opioids and other CNS depressants (alcohol, other sedatives, muscle relaxants): Concomitant use with Alprax increases the risk of profound sedation, respiratory depression, coma, and death. Combined use should be avoided unless no alternative exists, and if combined, doses and duration should be minimized with close monitoring.
• Ketoconazole and itraconazole (strong CYP3A4 inhibitors): Contraindicated with Alprax (see Contraindications); markedly increase Alprax plasma concentrations and sedative effect.
• Other moderate CYP3A4 inhibitors (e.g., fluoxetine, fluvoxamine, cimetidine, erythromycin, certain protease inhibitors, grapefruit juice): May increase Alprax plasma levels; dose reduction and monitoring may be needed.
• CYP3A4 inducers (e.g., carbamazepine, rifampin): May decrease the effectiveness of Alprax by lowering plasma concentrations.
• Digoxin: Alprax may increase serum digoxin concentrations, particularly in elderly patients; monitor for digoxin toxicity.

Common

• Drowsiness and sedation
• Dizziness, light-headedness
• Fatigue, weakness
• Impaired coordination (ataxia)
• Memory impairment / anterograde amnesia
• Dry mouth, constipation
• Irritability, weight changes

Serious (seek medical attention)

• Respiratory depression, especially when combined with opioids or other CNS depressants (see Precautions and Warnings)
• Physical dependence, misuse, and withdrawal symptoms, including seizures, on abrupt discontinuation
• Paradoxical reactions - agitation, aggression, hallucinations, disinhibition (more common in children and the elderly)
• Cognitive impairment and increased fall risk, particularly in elderly patients
• Rare: severe allergic reactions, jaundice, suicidal thoughts or worsening depression

Pregnancy: Alprax should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician must always be consulted before use in pregnancy. Benzodiazepine use, particularly in the third trimester or near delivery, has been associated with neonatal sedation, hypotonia, feeding difficulties (floppy infant syndrome), and neonatal withdrawal symptoms. Some data suggest a possible small increase in risk of congenital malformations with first-trimester exposure, though evidence is not conclusive. Alprax should not be discontinued abruptly in a pregnant patient who is dependent on it, as this can be harmful to both mother and fetus; any change should be supervised by a physician.

Lactation: Alprax is excreted into breast milk and may cause sedation, poor feeding, or weight loss in a breastfed infant. Use during breastfeeding is generally not recommended; if considered necessary, it should be under close medical supervision with monitoring of the infant.

Other important precautions

• Elderly patients: Increased sensitivity to sedative effects; higher risk of falls, fractures, confusion, and paradoxical reactions. Lower starting doses are recommended.
• Respiratory disease: Use with caution in patients with compromised respiratory function (e.g., COPD, sleep apnea) due to risk of respiratory depression.
• Hepatic or renal impairment: Reduced clearance may require dose adjustment.
• Depression / suicidal ideation: Use with caution in patients with depression; benzodiazepines have been associated with worsening of depression and emergence of suicidal ideation in some patients.
• Tolerance: Effectiveness may diminish with prolonged regular use.
• Driving/operating machinery: Alprax can impair alertness and coordination; avoid activities requiring mental alertness until effects are known.
• Alcohol: Avoid alcohol while taking Alprax due to additive CNS depression.

Overdose of Alprax can cause somnolence, confusion, impaired coordination, slurred speech, and in severe cases, profound CNS and respiratory depression, coma, and death - particularly when combined with alcohol or other CNS depressants such as opioids. Suspected overdose is a medical emergency: seek immediate medical attention or contact emergency services / a poison control center. Treatment is generally supportive (airway management, monitoring of vital signs); a specific benzodiazepine antagonist may be used by medical professionals in a controlled setting in select cases, but carries its own risks and must not be attempted outside a hospital setting. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep in a secure place out of reach of children and away from anyone for whom it was not prescribed, given its potential for misuse.

Elderly: Increased sensitivity to sedative and psychomotor effects; use lower starting doses and titrate cautiously (see Precautions and Warnings).

Pediatric: Safety and efficacy of Alprax have not been established in patients under 18 years of age (see Pediatric Uses).

Hepatic impairment: Reduced metabolism; use lower doses with caution.

Renal impairment: Use with caution; clinical experience is limited but dose adjustment may be warranted in significant impairment.

Pregnancy and lactation: See Pregnancy and Lactation section.

History of substance use disorder: Use with heightened caution and close monitoring given elevated risk of misuse and dependence with Alprax.

Alprax is generally intended for short-term or intermittent use. Treatment duration and the need for continued therapy should be periodically reassessed by the prescribing physician. Long-term continuous use increases the risk of tolerance, physical dependence, and withdrawal difficulty, and should only be undertaken with careful medical judgment and follow-up. Any discontinuation after prolonged use must follow a gradual taper (see Precautions and Warnings).

Benzodiazepines; Anxiolytics; Sedative-hypnotics

Alprazolam potentiates the effect of GABA at the GABA-A receptor in the central nervous system, increasing chloride channel opening frequency and producing central nervous system depression, which underlies its anxiolytic and sedative effects.

D

The safety and effectiveness of Alprax have not been established in pediatric patients (under 18 years of age). Alprax is not recommended for use in children. If anxiety-related treatment is required in a child or adolescent, alternative approaches and specialist evaluation should be considered, and any use of Alprax in this population should only occur under close specialist supervision when no suitable alternative exists.